Role of Anti-PCSK9 Antibodies in the Treatment of Patients with Statin Intolerance

Author(s): Julia Schreml, Ioanna Gouni-Berthold*.

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 13 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Statin intolerance is usually defined as the inability of a patient to tolerate statintreatment due to muscle-related complaints. While randomised trials show that these complaints occure with similar frequency in patients receiving placebo, namely in up to ~5% of the subjects, and data from registries as well as clinical experience indicate a much higher frequency of up to ~30%. The lack of standard definition or of a diagnostic marker of statin intolerance confounds the problem. The diagnosis remains subjective based on the symptoms the patient reports. Therefore, a large number of patients who need a statin are not receiving it, or receiving only very-low and/or intermittent doses unable to achieve a robust decrease in low-density lipoprotein cholesterol (LDL-C), leaving patients at high or very high risk for cardiovascular events requiring an alternative form of lipid-lowering therapy. Until recently, the only available alternatives were niacin, ezetimibe, bile-acid sequestrants and fibrates that decrease LDL-C concentrations by up to 15-20%. Recently the fully human monoclonal antibodies against proprotein convertase subtilisin/kexin 9 (PCSK9), alirocumab (Praluent®) and evolocumab (Repatha®), which have been shown to decrease LDL-C by up to 70% have been approved in Europe for use in patients with primary hypercholesterolemia not at LDL-C target while on maximally tolerated lipid-lowering therapy and specifically for patients with statin intolerance and in the USA for patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia requiring additional LDL-C lowering. Ongoing large clinical trials with cardiovascular endpoints will provide a definitive answer for the role of anti-PCSK9 antibodies in clinical practice.

Keywords: Alirocumab, anti-PCSK9 antibody, evolocumab, ezetimibe, PCSK9, statin, statin intolerance.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 13
Year: 2018
Page: [1538 - 1548]
Pages: 11
DOI: 10.2174/0929867324666170616111647
Price: $58

Article Metrics

PDF: 29
HTML: 3
EPUB: 1
PRC: 1